Tandem Diabetes Care (Nasdaq:TNDM) shares took a bit hit after hours on second-quarter results that missed the consensus forecast.
Shares of TNDM were down 7.2% at $64 per share after the market closed, which was when it released its quarterly results.
The San Diego-based automated insulin delivery technology developer posted losses of $15.1 million, or 24¢ per share, on sales of $200.3 million for the three months ended June 30, 2022, for a roughly $20 million bottom-line slide into the red on sales growth of 16.3%.
On Wall Street, analysts had been looking for sales of $205.3 million and adjusted earnings per share of 2¢.
Get the full story at our sister site, Drug Delivery Business News.